Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 12, 2021

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions

Peritoneal Carcinoma MetastaticPleural Effusion, MalignantHER2 Positive Malignancies

Interventions

BIOLOGICAL

Dual-targeting HER2 and PD-L1 CAR-T cells

HER2-positive solid tumor serosal cavity infusion

Trial Locations (1)

RECRUITING

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors

lead

Sichuan University

OTHER